The present study is the first study that investigated the modulatory effects of ERK/Ras inhibitors, XMD8-92, and salirasib, on protein and mRNA expression of p-ERK, cyclin D1, and eIF4B in CCA cell lines. Here, EIF4B is linked to cholangiocarcinoma.